Literature DB >> 15872357

Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.

Theodosia Maina1, Berthold A Nock, Hanwen Zhang, Anastasia Nikolopoulou, Beatrice Waser, Jean-Claude Reubi, Helmut R Maecke.   

Abstract

UNLABELLED: The biologic profiles of [(99m)Tc]Demobesin 1 ([(99m)Tc-N(4)(0-1),bzlg(0),d-Phe(6),Leu-NHEt(13),des-Met(14)]BB(6-14)) and [(111)In]Z-070 were compared using various gastrin-releasing peptide receptor GRP-R)-expressing tissues of human and animal origin.
METHODS: The binding affinities of Demobesin 1, Z-070, and its metallated analogs were determined by receptor autoradiography on human cancer biopsy and mouse pancreas samples and by binding assays in rat AR4-2J and human PC-3 cell membranes. Biodistribution of [(99m)Tc]Demobesin 1 and [(111)In]Z-070 was compared in nude mice bearing AR4-2J and PC-3 xenografts.
RESULTS: Demobesin 1, Z-070, and metallated Z-070 showed high affinity for the rat GRP-R in AR4-2J cell membranes (50% inhibitory concentration values = 0.17-0.45 nmol/L). In human PC-3 cell membranes, Demobesin 1 showed 11- to 15-fold higher affinity than the Z-070 peptides. These data were corroborated by results from human cancers and mouse pancreas. In AR4-2J and PC-3 tumor-bearing mice, [(99m)Tc]Demobesin 1 and [(111)In]Z-070 displayed similar uptake in the rat tumor. However, in the human PC-3 xenografts, [(99m)Tc]Demobesin 1 showed a 2- to 3-fold higher uptake than [(111)In]Z-070.
CONCLUSION: Considerable differences between rat or mouse and human GRP-R-expressing tissues were found for the in vitro and in vivo characteristics of 2 radiolabeled bombesin analogs. This finding may have a significant impact in the selection of experimental tools in the development of bombesin analogs for GRP-R-targeting applications in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15872357

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors.

Authors:  Adam F Prasanphanich; Lauren Retzloff; Stephanie R Lane; Prasant K Nanda; Gary L Sieckman; Tammy L Rold; Lixin Ma; Said D Figueroa; Samantha V Sublett; Timothy J Hoffman; Charles J Smith
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

Review 2.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 3.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

4.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

5.  Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.

Authors:  Maarten Brom; Wietske Woliner-van der Weg; Lieke Joosten; Cathelijne Frielink; Thomas Bouckenooghe; Paul Rijken; Karolina Andralojc; Burkhard J Göke; Marion de Jong; Decio L Eizirik; Martin Béhé; Tony Lahoutte; Wim J G Oyen; Cees J Tack; Marcel Janssen; Otto C Boerman; Martin Gotthardt
Journal:  Diabetologia       Date:  2014-02-01       Impact factor: 10.122

6.  Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA.

Authors:  Beatrice Waser; Véronique Eltschinger; Karen Linder; Adrian Nunn; Jean Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-15       Impact factor: 9.236

7.  Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.

Authors:  Beatrice Waser; Jean Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

8.  Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

Authors:  M de Visser; H F Bernard; J L Erion; M A Schmidt; A Srinivasan; B Waser; J C Reubi; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 9.236

Review 9.  Molecular probes for the in vivo imaging of cancer.

Authors:  Raphael Alford; Mikako Ogawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Biosyst       Date:  2009-08-19

10.  Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.

Authors:  Xuejuan Wang; Melpomeni Fani; Stefan Schulz; Jean Rivier; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-29       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.